abemaciclib · Eli Lilly And Co · NDA 208716
Verzenio
Earliest generic entry, as listed · earliest of 4 marketed strengths
28 Sep 2031
Blocked by patent: US 7855211, US 7855211, US 7855211, US 7855211, US 7855211.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7855211 | substance, product, use U-2135 | 28 Sep 2031 |
| US 7855211 | substance, product, use U-1981 | 28 Sep 2031 |
| US 7855211 | substance, product, use U-3546 | 28 Sep 2031 |
| US 7855211 | substance, product, use U-3265 | 28 Sep 2031 |
| US 7855211 | substance, product, use U-3242 | 28 Sep 2031 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic tentatively approved · 208716-0016 Nov 2025
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208716 · 001 · RLD | tablet, oral | 50MG | 28 Sep 2031 |
| 208716 · 002 · RLD | tablet, oral | 100MG | 28 Sep 2031 |
| 208716 · 003 · RLD | tablet, oral | 150MG | 28 Sep 2031 |
| 208716 · 004 · RLD | tablet, oral | 200MG | 28 Sep 2031 |